Clinical trials: Age Related Maculopathy
Neovascular Age-related Macular Degeneration
Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration
Purpose and rationale: To demonstrate similar efficacy, safety and immunogenicity of SOK583A1 and Eylea EU as per Eylea approved treatment regimen in patients with nAMD.
- Trial name
- Mylight (NCT04864834)
- Testing
- SOK583A1 (40 mg/mL), Eylea EU (40 mg/mL)
- Where
- 102 sites in United States, Australia and 14 more
- Volunteers
- 485 people
- Sponsor
- Sandoz
Neovascular Age-related Macular Degeneration
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
This main long-term extension study is designed to evaluate the long-term safety and tolerability of faricimab 6 milligrams (mg) administered by intravitreal injection at a personalized treatment interval (PTI) to participants…
- Trial name
- AVONELLE-X (NCT04777201)
- Testing
- Faricimab, Anti-VEGF Therapy
- Where
- 251 sites in United States, Argentina and 25 more
- Volunteers
- 1,036 people
- Sponsor
- Hoffmann-La Roche
Geographic Atrophy
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related…
- Trial name
- NCT06161584
- Testing
- Pegcetacoplan
- Where
- 34 sites in United States
- Volunteers
- 300 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Age-Related Macular Degeneration
Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
KH631 is a adeno-associated virus (AAV) vector-based gene therapy for subretinal injection. The long-term, stable therapeutic protein after one time injection for nAMD could potentially reduce the treatment burden and maintain…
- Trial name
- NCT05672121
- Testing
- KH631
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Chengdu Origen Biotechnology Co., Ltd.
Epiretinal Membrane, Dry Age Related Macular Degeneration
(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000
This study will measure how well PathFinder 1.0 detects retinal abnormalities on macular cube OCT B-scans by assessing its sensitivity and specificity.
- Conditions
- Epiretinal Membrane, Dry Age Related Macular Degeneration, Macular Abnormalities, Retina Disease
- Trial name
- NCT07680244
- Testing
- PathFinder 1.0 on CIRRUS HD-OCT
- Where
- 6 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Carl Zeiss Meditec-Dublin CoCe
Wet Age-Related Macular Degeneration
Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration
The purpose of the study was to compare the effect of intravitreal injections of ranibizumab and aflibercept on systemic VEGF protein levels in treatment naïve wet neovascular Age-related Macular Degeneration (wAMD) patients in a…
- Trial name
- TIDE AMD (NCT02257632)
- Testing
- Ranibizumab 0.5 mg, Aflibercept 2 mg
- Where
- 6 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Macular Degeneration
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
Part A (Phase IIa): Primary objectives: The study part A is designed to investigate whether the use of regorafenib eye drops can help patients with neovascular (wet) Age-Related Macular Degeneration (wAMD) to see better after 4…
- Trial name
- DREAM (NCT02222207)
- Testing
- Regorafenib, ophthalmic oily suspension (BAY73-4506), Ranibizumab
- Where
- 149 sites in United States, Australia and 16 more
- Volunteers
- 52 people
- Sponsor
- Bayer
Age-Related Macular Degeneration, Wet Macular Degeneration
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
The purpose of this study is to confirm the clinical and economic benefits of IRay treatment with respect to the number of anti-VEGF injections and frequency of visits during the first year after treatment for patients with wet…
- Conditions
- Age-Related Macular Degeneration, Wet Macular Degeneration, Macular Degeneration, Eye Diseases
- Trial name
- ENDEAVOUR (NCT01521065)
- Testing
- IRay
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- Oraya Therapeutics, Inc.
"Wet" Age-Related Macular Degeneration
A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular Degeneration
Age-Related Macular Degeneration (AMD) is a degenerative eye disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of blindness among adults age 50 or older in the Western world.
- Trial name
- NCT00139282
- Testing
- Squalamine Lactate
- Where
- 29 sites in United States
- Sponsor
- Genaera Corporation
Complement Mediated Diseases
First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers
Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a Single Ascending Dose (SAD) and a Multiple Dose (MD) of the complement inhibitor AMY-101.
- Trial name
- NCT03316521
- Testing
- AMY-101
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Amyndas Pharmaceuticals S.A.
Neovascular Age-Related Macular Degeneration
Safety and Tolerability Study for Age-Related Macular Degeneration
Phase 1: The purpose of this study is to evaluate the safety and tolerability of single ascending doses of hI-con1™ for subjects with Age-Related Macular Degeneration.
- Trial name
- NCT01485588
- Testing
- hI-con1™ 60µl, hI-con1™ 150µl, hI-con1™ 300µl
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Iconic Therapeutics, Inc.
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema
Ocular Safety and Usability Study for FYB201 PFS
The objective of the study is to assess the ocular safety of the FYB201 pre-filled syringe in terms of preparation and administration by Retina Specialists in the clinical setting.
- Conditions
- Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema
- Trial name
- NCT06708624
- Testing
- FYB201 0.5 mg (0.05 mL of 10 mg/mL)
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Formycon AG
Macular Degeneration
Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)
This is s randomized, multi-center, double blind, 3 arm, phase I/II pilot study to evaluate the safety and efficacy of treatment with ORA102 combined with Avastin (Bevacizumab) versus Avastin alone, in patients with neo-vascular…
- Trial name
- NCT00745511
- Testing
- ORA102 and Avastin, Avastin
- Where
- 5 sites in Israel
- Volunteers
- 96 people
- Sponsor
- Ora Bio Ltd.
Neovascular Age-related Macular Degeneration
A Study of Longer Interval of IVT IBI302 in Subjects With nAMD
The study is designed for multi-center, randomized, double-masked, active-controlled study to evaluate the longer interval of intravitreal injection of IBI302 in subjects with neovascular age-related macular degeneration.
- Trial name
- NCT05403749
- Testing
- dose 1 IBI302, Aflibercept, dose 2 IBI302
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Geographic Atrophy
A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
This is a dose finding study designed to evaluate the efficacy, safety, and pharmacokinetics of danicopan in participants with GA secondary to AMD.
- Trial name
- NCT05019521
- Testing
- Danicopan
- Where
- 128 sites in United States, Australia and 11 more
- Volunteers
- 365 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Macular Degeneration, Choroidal Neovascularization
Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease
The purpose of this study is to determine the safety and tolerability of Talaporfin Sodium (LS11) Photodynamic Therapy in patients with late stage Age-Related Macular Disease (AMD).
- Trial name
- NCT00102115
- Testing
- Talaporfin Sodium (LS11) Photodynamic Therapy (PDT)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Light Sciences LLC
Geographic Atrophy
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
This multicenter study will investigate the safety, tolerability, pharmacokinetics, and immunogenicity of RO7303359 following single intravitreal (ITV) injection in participants with geographic atrophy (GA) secondary to…
- Trial name
- NCT04615325
- Testing
- RO7303359
- Where
- 12 sites in United States
- Volunteers
- 37 people
- Sponsor
- Hoffmann-La Roche
Neovascular Wet Age-related Macular Degeneration (AMD)
Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD
The primary objective of the study is to investigate the safety of intravitreal (IVT) REGN2176-3 in patients with neovascular wet age-related macular degeneration (AMD).
- Trial name
- NCT02061865
- Testing
- REGN2176-3
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Regeneron Pharmaceuticals
Age-related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO)
Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada
The primary objective of this study is to measure physician knowledge and understanding of the key safety information contained in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the…
- Conditions
- Age-related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO), Diabetic Macular Edema (DME)
- Trial name
- NCT02585401
- Testing
- Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
- Where
- Canada
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Bayer
Neovascular Age-Related Macular Degeneration
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD
The objective of this study is to provide initial safety, tolerability and pharmacokinetics information of intravitreal administration of pegcetacoplan in order to support further development into larger Phase II studies for…
- Trial name
- ASAP II (NCT02461771)
- Testing
- Pegcetacoplan
- Where
- 4 sites in United States, Australia
- Volunteers
- 13 people
- Sponsor
- Apellis Pharmaceuticals, Inc.